Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients
During IMS 2023, Hans Jacobs presented the work done by his team and Sebia highlighting the fact that MS-MRD (M-inSight®) is feasible in 100% of patients with MM, with a sensibility 1000-fold higher than currently used M-protein diagnostics. The dynamic monitoring revealed biochemical relapse on average 455 days earlier compared to SPE. Finally, SILuMAB can be used as off-the-shelf calibrator for MS-MRD M-protein quantification.